AR011229A1 - Compuestos derivados de adenosina antagonistas en el receptor ai adenosina, procesos para su preparacion, composiciones farmaceuticas que los contieneny su uso en medicina. - Google Patents
Compuestos derivados de adenosina antagonistas en el receptor ai adenosina, procesos para su preparacion, composiciones farmaceuticas que los contieneny su uso en medicina.Info
- Publication number
- AR011229A1 AR011229A1 ARP980105590A ARP980105590A AR011229A1 AR 011229 A1 AR011229 A1 AR 011229A1 AR P980105590 A ARP980105590 A AR P980105590A AR P980105590 A ARP980105590 A AR P980105590A AR 011229 A1 AR011229 A1 AR 011229A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- ring
- group
- optionally substituted
- adenosine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
Abstract
Un compuesto de la formula (I) el cual es un agonista en el receptor de la adenosina Al, en donde: R2 es alquilo con 1 a 3 átomos, halogeno ohidrogeno; R3 es un grupo alquilo recto o ramificado, fluorado, de 1-6 átomos de carbono; R1 es un grupo seleccionado de: (1) -(alq)n-(C3-7)-cicloalquilo,que incluyen el cicloalquilo con puentes, el grupo cicloalquilo que está substituido opcionalmente por uno o más de los substituyentes seleccionados deOH, halogeno, -(C1-3) alcoxi, en donde (alq) es alquileno con C1-3 y n es 0 o 1; (2) un grupo heterocíclico alifático de anillos de 4 a 6 elementos quecontienen al menos un heteroátomo seleccionado de O, N o S, substituido opcionalmente por uno o más substituyentes seleccionados del grupo queconsiste de -(C1-3)alquilo, -CO2-(C1-4)alquilo, -CO(C1-3alquilo), -S(=O)n-(C 1-3alquilo), - CONRaRb (en donde Ra y Rb son independientemente H o C1-3alquilo) o =O; en donde existe un átomo de azufre en el anillo heterocíclico, y el azufre está substituido opcionalmente por (=O)n, en donde n es 1 o 2; (3)alquilo con C1-12 recto o ramificado, que incluye opcionalmente uno o más O, S (=O)n (en donde n es 0, 1 o 2) o grupos N substituidos dentro de la cadena dealquilo substituido poruno o más de los siguientes grupos, fenilo, halogeno, hidroxi o NRaRb en donde Ra y Rb ambos son C1-3 alquilo o hidrogeno; (4) unanillo aromático bicíclico fusionado (formula (II), en donde B es un grupo aromático heterocíclico de 5 o 6 elementos que contiene 1 o más átomos de O, No S, en donde el anillo bicíclico está unido al átomo de nitrogeno de la formula (I) por medio de un átomo del anillo A y el anillo B está substituidoopcionalmente por -CO2-(C1-3alquilo); (5) un grupo fenilo substituido opcionalmente por uno o más substituyentes seleccionados de: halogeno, -SO3H,
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9723589.9A GB9723589D0 (en) | 1997-11-08 | 1997-11-08 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
AR011229A1 true AR011229A1 (es) | 2000-08-02 |
Family
ID=10821760
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980105590A AR011229A1 (es) | 1997-11-08 | 1998-11-05 | Compuestos derivados de adenosina antagonistas en el receptor ai adenosina, procesos para su preparacion, composiciones farmaceuticas que los contieneny su uso en medicina. |
Country Status (29)
Country | Link |
---|---|
US (1) | US6455510B1 (es) |
EP (2) | EP1457495A1 (es) |
JP (1) | JP2001522857A (es) |
KR (1) | KR20010031875A (es) |
CN (1) | CN1285843A (es) |
AP (1) | AP2000001801A0 (es) |
AR (1) | AR011229A1 (es) |
AT (1) | ATE273990T1 (es) |
AU (1) | AU2048399A (es) |
BR (1) | BR9813976A (es) |
CA (1) | CA2309200A1 (es) |
CO (1) | CO5021135A1 (es) |
DE (1) | DE69825780T2 (es) |
EA (1) | EA200000392A1 (es) |
EE (1) | EE200000285A (es) |
ES (1) | ES2222621T3 (es) |
GB (1) | GB9723589D0 (es) |
HR (1) | HRP20000275A2 (es) |
HU (1) | HUP0004082A2 (es) |
IL (1) | IL135964A0 (es) |
IS (1) | IS5477A (es) |
MA (1) | MA26565A1 (es) |
NO (1) | NO20002361L (es) |
PE (1) | PE20000013A1 (es) |
PL (1) | PL340921A1 (es) |
SK (1) | SK6722000A3 (es) |
TR (1) | TR200002131T2 (es) |
WO (1) | WO1999024449A2 (es) |
ZA (1) | ZA9810125B (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9723589D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
GB0106867D0 (en) | 2001-03-20 | 2001-05-09 | Glaxo Group Ltd | Process |
US20040162422A1 (en) * | 2001-03-20 | 2004-08-19 | Adrian Hall | Chemical compounds |
US6946449B2 (en) | 2001-07-13 | 2005-09-20 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
US7157440B2 (en) | 2001-07-13 | 2007-01-02 | Cv Therapeutics, Inc. | Partial and full agonists of A1 adenosine receptors |
US7713946B2 (en) | 2002-07-11 | 2010-05-11 | Cv Therapeutics, Inc. | Partial and full agonists A1 adenosine receptors |
WO2003029264A2 (en) | 2001-10-01 | 2003-04-10 | University Of Virginia Patent Foundation | 2-propynyl adenosine analogs having a2a agonist activity and compositions thereof |
EP1375508A1 (en) * | 2002-06-27 | 2004-01-02 | Aventis Pharma Deutschland GmbH | N6-substituted adenosine analogues and their use as pharmaceutical agents |
US7265111B2 (en) * | 2002-06-27 | 2007-09-04 | Sanofi-Aventis Deutschland Gmbh | Adenosine analogues and their use as pharmaceutical agents |
FR2842810B1 (fr) * | 2002-07-25 | 2006-01-27 | Inst Nat Sciences Appliq | Nouveaux composes gem difluores, leur procedes de preparation et leurs applications. |
WO2004016635A2 (en) * | 2002-08-15 | 2004-02-26 | Cv Therapeutics, Inc. | Partial and full agonists of a1 adenosine receptors |
AU2004209986C1 (en) | 2003-02-03 | 2009-08-13 | Gilead Palo Alto, Inc. | Partial and full agonists of A1 adenosine receptors |
AR044519A1 (es) | 2003-05-02 | 2005-09-14 | Novartis Ag | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina |
GB0401334D0 (en) | 2004-01-21 | 2004-02-25 | Novartis Ag | Organic compounds |
GB0411056D0 (en) | 2004-05-18 | 2004-06-23 | Novartis Ag | Organic compounds |
WO2006031505A1 (en) * | 2004-09-09 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Purine derivatives as a3 and a1 adenosine receptor agonists |
GB0424284D0 (en) | 2004-11-02 | 2004-12-01 | Novartis Ag | Organic compounds |
GB0426164D0 (en) | 2004-11-29 | 2004-12-29 | Novartis Ag | Organic compounds |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
CA2625664C (en) | 2005-10-21 | 2016-01-05 | Novartis Ag | Human antibodies against il13 and therapeutic uses |
GB0601951D0 (en) | 2006-01-31 | 2006-03-15 | Novartis Ag | Organic compounds |
WO2007120972A2 (en) * | 2006-02-10 | 2007-10-25 | University Of Virginia Patent Foundation | Method to treat sickle cell disease |
US8188063B2 (en) * | 2006-06-19 | 2012-05-29 | University Of Virginia Patent Foundation | Use of adenosine A2A modulators to treat spinal cord injury |
US20090286779A1 (en) | 2006-09-29 | 2009-11-19 | Novartis Ag | Pyrazolopyrimidines as lipid kinase inhibitors |
RU2009120389A (ru) | 2006-10-30 | 2010-12-10 | Новартис АГ (CH) | Гетероциклические соединения в качестве противовоспалительных агентов |
US8058259B2 (en) * | 2007-12-20 | 2011-11-15 | University Of Virginia Patent Foundation | Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists |
CA2711495A1 (en) * | 2008-01-09 | 2009-07-16 | Pgxhealth Llc | Intrathecal treatment of neuropathic pain with a2ar agonists |
KR20100113557A (ko) | 2008-01-11 | 2010-10-21 | 노파르티스 아게 | 키나제 억제제로서의 피리미딘 |
JP2012516345A (ja) | 2009-01-29 | 2012-07-19 | ノバルティス アーゲー | 星細胞腫治療用置換ベンゾイミダゾール |
US8389526B2 (en) | 2009-08-07 | 2013-03-05 | Novartis Ag | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives |
MX2012001838A (es) | 2009-08-12 | 2012-02-29 | Novartis Ag | Compuestos de hidrazona heterociclico y sus usos para tratar cancer e inflamacion. |
CN105078978A (zh) | 2009-08-17 | 2015-11-25 | 因特利凯公司 | 杂环化合物及其用途 |
EP2467383A1 (en) | 2009-08-20 | 2012-06-27 | Novartis AG | Heterocyclic oxime compounds |
WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
US20130324526A1 (en) | 2011-02-10 | 2013-12-05 | Novartis Ag | [1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase |
EP2678016B1 (en) | 2011-02-23 | 2016-08-10 | Intellikine, LLC | Heterocyclic compounds and uses thereof |
PE20140378A1 (es) | 2011-02-25 | 2014-03-28 | Irm Llc | Compuestos y composiciones como inhibidores de la trk |
DE102011005232A1 (de) | 2011-03-08 | 2012-09-13 | AristoCon GmbH & Co. KG | Adenosin und seine Derivate zur Verwendung in der Schmerztherapie |
EP2755976B1 (en) | 2011-09-15 | 2018-07-18 | Novartis AG | 6-substituted 3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyridines as c-met tyrosine kinase inhibitors |
EP2793893A4 (en) | 2011-11-23 | 2015-07-08 | Intellikine Llc | IMPROVED TREATMENT REGIMES USING MTOR INHIBITORS |
WO2013149581A1 (en) | 2012-04-03 | 2013-10-10 | Novartis Ag | Combination products with tyrosine kinase inhibitors and their use |
JP2016512835A (ja) | 2013-03-15 | 2016-05-09 | インテリカイン, エルエルシー | キナーゼ阻害剤の組み合わせ及びそれらの使用 |
WO2015084804A1 (en) | 2013-12-03 | 2015-06-11 | Novartis Ag | Combination of mdm2 inhibitor and braf inhibitor and their use |
WO2016011658A1 (en) | 2014-07-25 | 2016-01-28 | Novartis Ag | Combination therapy |
MX2017001461A (es) | 2014-07-31 | 2017-05-11 | Novartis Ag | Terapia de combinacion. |
TW202140550A (zh) | 2020-01-29 | 2021-11-01 | 瑞士商諾華公司 | 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3575959A (en) * | 1969-05-13 | 1971-04-20 | Merck & Co Inc | 5'-substituted ribofuranosyl nucleosides |
US5589467A (en) * | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
AU2022597A (en) * | 1996-03-13 | 1997-10-01 | Novo Nordisk A/S | A method of treating disorders related to cytokines in mammals |
GB9610031D0 (en) | 1996-05-14 | 1996-07-17 | Glaxo Group Ltd | Chemical compounds |
GB9723589D0 (en) * | 1997-11-08 | 1998-01-07 | Glaxo Group Ltd | Chemical compounds |
-
1997
- 1997-11-08 GB GBGB9723589.9A patent/GB9723589D0/en not_active Ceased
-
1998
- 1998-11-05 CO CO98065179A patent/CO5021135A1/es unknown
- 1998-11-05 AR ARP980105590A patent/AR011229A1/es unknown
- 1998-11-05 PE PE1998001065A patent/PE20000013A1/es not_active Application Discontinuation
- 1998-11-05 ZA ZA9810125A patent/ZA9810125B/xx unknown
- 1998-11-05 MA MA25336A patent/MA26565A1/fr unknown
- 1998-11-06 AP APAP/P/2000/001801A patent/AP2000001801A0/en unknown
- 1998-11-06 DE DE1998625780 patent/DE69825780T2/de not_active Expired - Fee Related
- 1998-11-06 WO PCT/EP1998/007021 patent/WO1999024449A2/en active IP Right Grant
- 1998-11-06 KR KR1020007004959A patent/KR20010031875A/ko not_active Application Discontinuation
- 1998-11-06 AT AT98965151T patent/ATE273990T1/de not_active IP Right Cessation
- 1998-11-06 EA EA200000392A patent/EA200000392A1/ru unknown
- 1998-11-06 TR TR2000/02131T patent/TR200002131T2/xx unknown
- 1998-11-06 CA CA002309200A patent/CA2309200A1/en not_active Abandoned
- 1998-11-06 BR BR9813976-2A patent/BR9813976A/pt not_active Application Discontinuation
- 1998-11-06 HU HU0004082A patent/HUP0004082A2/hu unknown
- 1998-11-06 EP EP04076482A patent/EP1457495A1/en not_active Withdrawn
- 1998-11-06 EE EEP200000285A patent/EE200000285A/xx unknown
- 1998-11-06 JP JP2000520457A patent/JP2001522857A/ja active Pending
- 1998-11-06 EP EP98965151A patent/EP1030857B1/en not_active Expired - Lifetime
- 1998-11-06 CN CN98812979A patent/CN1285843A/zh active Pending
- 1998-11-06 PL PL98340921A patent/PL340921A1/xx unknown
- 1998-11-06 SK SK672-2000A patent/SK6722000A3/sk unknown
- 1998-11-06 US US09/530,573 patent/US6455510B1/en not_active Expired - Fee Related
- 1998-11-06 ES ES98965151T patent/ES2222621T3/es not_active Expired - Lifetime
- 1998-11-06 AU AU20483/99A patent/AU2048399A/en not_active Abandoned
- 1998-11-06 IL IL13596498A patent/IL135964A0/xx unknown
-
2000
- 2000-05-03 IS IS5477A patent/IS5477A/is unknown
- 2000-05-05 NO NO20002361A patent/NO20002361L/no not_active Application Discontinuation
- 2000-05-08 HR HR20000275A patent/HRP20000275A2/hr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IS5477A (is) | 2000-05-03 |
NO20002361D0 (no) | 2000-05-05 |
JP2001522857A (ja) | 2001-11-20 |
AP2000001801A0 (en) | 2000-06-30 |
NO20002361L (no) | 2000-07-05 |
KR20010031875A (ko) | 2001-04-16 |
EP1030857A2 (en) | 2000-08-30 |
AU2048399A (en) | 1999-05-31 |
ATE273990T1 (de) | 2004-09-15 |
CO5021135A1 (es) | 2001-03-27 |
BR9813976A (pt) | 2000-09-26 |
US6455510B1 (en) | 2002-09-24 |
EE200000285A (et) | 2001-08-15 |
CN1285843A (zh) | 2001-02-28 |
EA200000392A1 (ru) | 2000-12-25 |
CA2309200A1 (en) | 1999-05-20 |
HUP0004082A2 (hu) | 2001-04-28 |
IL135964A0 (en) | 2001-05-20 |
EP1030857B1 (en) | 2004-08-18 |
GB9723589D0 (en) | 1998-01-07 |
PE20000013A1 (es) | 2000-01-21 |
DE69825780T2 (de) | 2005-01-13 |
ES2222621T3 (es) | 2005-02-01 |
SK6722000A3 (en) | 2001-01-18 |
TR200002131T2 (tr) | 2001-01-22 |
WO1999024449A3 (en) | 1999-08-19 |
ZA9810125B (en) | 2000-05-05 |
PL340921A1 (en) | 2001-03-12 |
WO1999024449A2 (en) | 1999-05-20 |
MA26565A1 (fr) | 2004-12-20 |
EP1457495A1 (en) | 2004-09-15 |
DE69825780D1 (de) | 2004-09-23 |
HRP20000275A2 (en) | 2000-12-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR011229A1 (es) | Compuestos derivados de adenosina antagonistas en el receptor ai adenosina, procesos para su preparacion, composiciones farmaceuticas que los contieneny su uso en medicina. | |
AR018917A1 (es) | Compuestos derivados de adenosina que son agonistas en el receptor adenosina a1, proceso para su preparacion, composiciones farmaceuticas que los contienen. | |
ATE380818T1 (de) | Piperazine-substituierte aryl-benzodiazepinen und ihre verwendung als dopaminrezeptor-antagonisten zur behandlung von psychose | |
CO5070570A1 (es) | DERIVADOS DE TIROSINA COMO ACTIVADORES DE hPPAR Y hPPARalfa Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE | |
TR200002157T2 (tr) | Kimyasal bileşikler | |
ES2161231T3 (es) | Compuestos heterociclicos como antagonistas de bradiquinina. | |
ES2140391T3 (es) | Derivados de dialcoxi-piridinil-bencimidazol, procedimiento para su preparacion y su uso farmaceutico. | |
ES2055056T3 (es) | Derivados de pirimidopirimidina. | |
ATE331726T1 (de) | Adenine-derivate | |
NO902954D0 (no) | Fremgangsmaate for fremstilling av substituerte kinazolinoner som angitensin ii-antagonister. | |
MX9206939A (es) | Derivados de piperazina, procedimiento para su preparacion y composicion farmaceutica que los comprende | |
AR013815A1 (es) | NUEVOS DERIVADOS DEL ACIDO 4-FORMIL-4, 4a, 5, 6, 7, 7a, 8, 8a-OCTAHIDRO- 7-METIL-3-(1-METILETIL)-1,4-METANO-S-INDACEN-3a(1H)-CARBOXILICO, UN PROCESOPARA SU PREPARACION, SU USO EN LA FABRICACION DE UN MEDICAMENTO Y UNA COMPOSICION FARMACEUTICA QUE LOS CONTIENE. | |
ES2052521T3 (es) | Derivados de aminoimidazoquinolina. | |
DK100588D0 (da) | 3-amino-dihydro-(1)-benzopyraner og -benzothiopyraner | |
DE3679378D1 (de) | 3-amino-dihydro-(1)-benzopyrane und benzothiopyrane. | |
FI852003L (fi) | --laktamantibiotika, foerfarande foer deras framstaellning och deras anvaendning som laekemedel eller tillvaextbefraemjare vid boskapsuppfoedning eller som antioxidanter. | |
PE86698A1 (es) | Derivados de indolina | |
AR020773A1 (es) | Compuesto derivados de 3-(tetrahidropiridin-4-il)indol, metodo para prepararlo, una composicion farmaceutica que los contiene, metodo para preparar dicha composicion y uso del compuesto | |
MX9102667A (es) | Mejoras en compuestos farmacologicamente activos y procedimiento para la preparacion de dichos compuestos. | |
ES2167725T3 (es) | Procedimiento para la coloracion de material organico de alto peso molecular, y pigmentos policiclicos. | |
ES2063157T3 (es) | Nuevos derivados del indol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
AR020121A1 (es) | Derivados de 1,3-oxazol, composicion farmaceutica que los comprende, procedimiento para la preparacion de dichos derivados y el uso de los mismospara la elaboracion de medicamentos utiles como antagonistas del receptor de vitronectina. | |
ES2134808T3 (es) | Compuestos antivirales oralmente activos. | |
AR033457A1 (es) | Compuesto de piperazina, composicion farmaceutica que lo comprende, su uso para preparar dicha composicion y procedimiento para prepararlo | |
PE50198A1 (es) | Derivados piperacino como antagonistas de neuroquinina |